Advicenne is open to any type of partnership and is actively looking for products to in-license or distribute on the European market in Advicenne’s areas of interest.
ADV7103 is an innovative formula presented as micro-tablets to treat an orphan renal disease. (Orphan and PUMA status)Find out more
News / events
6 Jul 2017
22 Jun 2017